Mercer Global Advisors’s Arbutus Biopharma ABUS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$106K Buy
22,093
+4,008
+22% +$19.3K ﹤0.01% 3586
2026
Q2
$86.8K Sell
18,085
-1,260
-7% -$5.53K ﹤0.01% 3447
2026
Q1
$87.1K Sell
19,345
-25,775
-57% -$113K ﹤0.01% 3051
2025
Q4
$217K Buy
45,120
+6,161
+16% +$27.7K ﹤0.01% 2493
2025
Q3
$177K Buy
38,959
+3,280
+9% +$12K ﹤0.01% 2418
2025
Q2
$110K Buy
35,679
+15,179
+74% +$50.4K ﹤0.01% 2148
2025
Q1
$71.5K Hold
20,500
– – ﹤0.01% 2078
2024
Q4
$67K Buy
+20,500
New +$75.4K ﹤0.01% 2069

Other funds holding ABUS

Mercer Global Advisors's ABUS Position: Q3 2026 in Review

Mercer Global Advisors increased its Arbutus Biopharma (ABUS) stake by 22% in Q3 2026, buying an estimated $19.3K and bringing the position to 22,093 shares worth $106K. The position accounts for ﹤0.01% of the portfolio, ranked #3586.

Mercer Global Advisors first reported a position in ABUS in Q4 2024 and has held it in 8 quarters since. The position peaked at $217K in Q4 2025. 216 funds tracked by Wall St. Rank hold ABUS as of Q3 2026.

  • Mercer Global Advisors held 22,093 shares of Arbutus Biopharma worth $106K as of Q3 2026.
  • Mercer Global Advisors bought 4,008 Arbutus Biopharma shares in Q3 2026, an estimated $19.3K.
  • Arbutus Biopharma made up ﹤0.01% of Mercer Global Advisors's portfolio in Q3 2026, its #3586 holding.
  • Mercer Global Advisors first reported a position in Arbutus Biopharma in Q4 2024 and has held it in 8 quarters since.
  • Mercer Global Advisors's Arbutus Biopharma position peaked at $217K in Q4 2025.
  • 216 funds tracked by Wall St. Rank held Arbutus Biopharma as of Q3 2026.

Based on Mercer Global Advisors's 13F filing for Q3 2026, filed 16 Nov 2026.